Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: In-vitro and in-vivo evaluations

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 461-475

  Özcan, Ipek ^a   Azizoǧlu, Erkan ^a   Senyiǧit, Taner ^a   Özyazici, Mine ^a   Özer, Özgen ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Anti inflammatory activity; Skin blanching; Skin permeation; TEWL

Indexed keywords

CHITOSAN; DIFLUCORTOLONE VALERATE; NANOPARTICLE; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREAM; DRUG ACCUMULATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; EPIDERMIS; EX VIVO STUDY; GEL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PAW EDEMA; RAT; SKIN PERMEABILITY; STRATUM CORNEUM; SUSTAINED DRUG RELEASE; VASOCONSTRICTION; VISCOSITY;

ANTI-INFLAMMATORY ACTIVITY; SKIN BLANCHING; SKIN PERMEATION; TEWL;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHITOSAN; DIFLUCORTOLONE; DRUG CARRIERS; EDEMA; GELS; LECITHINS; MALE; MECHANICAL PHENOMENA; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; VASOCONSTRICTION;

EID: 84873326866     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40519     Document Type: Article

References (44)

1. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3(1):47-58.
2. Patel HK, Barot BS, Parejiya PB, Shelat PK, Shukla A. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: ex vivo permeation and skin irritation studies. Colloids Surf B Biointerfaces. 2013;102:86-94.
3. Fontana MC, Rezer JF, Coradini K, Leal DB, Beck RC. Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm. 2011;79(2):241-249.
4. Fang JY, Wu PC, Huang YB, Tsai YH. In vitro permeation study of capsaicin and its synthetic derivatives from ointment bases using various skin types. Int J Pharm. 1995;126:119-128.
5. Senyigit T, Padula C, Ozer O, Santi P. Different approaches for improving skin accumulation of topical corticosteroids. Int J Pharm. 2009;380:155-160.
6. Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995;162(2):123-126.
7. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3(3): 141-147.
8. Gillet A, Compere P, Lecomte F, et al. Liposome surface charge influence on skin penetration behaviour. Int J Pharm. 2011;411(1-2): 223-231.
9. Schafer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-443.
10. Senyigit T, Ozcan I, Ozer O. Innovative topical formulations for treatment of dermatitis. Recent Pat Inflamm Allergy Drug Discov. 2012;6(3): 186-201.
11. Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine. 2012;7:1841-1850.
12. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63:470-491.
13. Rajan R, Vasudevan DT. Effect of permeation enhancers on the penetration mechanism of transfersomal gel of ketoconazole. J Adv Pharm Technol Res. 2012;3(2):112-116.
14. Hafner A, Lovrić J, Pepić I, Filipovic ́-Grc ̌ic ́ J. Lecithin/chitosan nanoparticles for transdermal delivery of melatonin. J Microencapsul. 2011;28(8):807-815.
15. Ozcan I, Senyigit T, Gökce EH, Ozer O. Current status of chitosan on dermal/transdermal drug delivery systems. In: Davis SP, editor. Chitosan: Manufacture, Properties and Usage. New York: NOVA Science Publishers, Inc; 2010:449-484.
16. Senyigit T, Sonvico F, Barbieri S, Ozer O, Santi P, Colombo P. Lecithin-chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Control Release. 2010;142(3):368-373.
17. Sonvico F, Cagnani A, Rossi A, et al. Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. Int J Pharm. 2006; 324:67-73.
18. Tan Q, Liu W, Guo C, Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomedicine. 2011;6:1621-1630.
19. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol. 2010;24(2):119-124.
20. Coleman GL, Kanfer I, Haigh JM. Comparative blanching activities of proprietary, diflucortolone valerate topical preparations. Dermatologica. 1978;156(4):224-230.
21. Haigh JM, Kanfer I. Assessment of topical corticosteroid preparations: the human skin blanching assay. Int J Pharm. 1984;19:245-262.
22. Schwarb FP, Smith EW, Haigh JM, Surber C. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Eur J Pharm Biopharm. 1999;47:261-267.
23. Jones DS, Lawlor MS, Woolfson AD. Examination of the flow rheological and textural properties of polymer gels composed of poly(methylvinylether-comaleic anhydride) and poly(vinylpyrrolidone): rheological and mathematical interpretation of textural parameters. J Pharm Sci. 2002;91(9):2090-2101.
24. Morris CJ. Carrageenan-induced paw edema in the rat and mouse from: methods in molecular biology. In: Winyard PG, Willoughby DA, editors. Inflammation Protocols. Totowa: Humana Press Inc; 2003: 115-121.
25. Wu PC, Chang JS, Huang YB, Chai CY, Tsai YH. Evaluation of percutaneous absorption and skin irritation of ketoprofen through rat skin: in vitro and in vivo study. Int J Pharm. 2001;222:225-235.
26. Barel AO, Clarys P. Study of the stratum corneum barrier function by transepidermal water woss measurements: comparison between two commercial instruments: Evaporimeter® and Tewameter®. Skin Pharmacol. 1995;8(4):186-195.
27. Jain S, Mittal A, Amit JK. Enhanced topical delivery of cyclosporine-A using PLGA nanoparticles as carrier. Curr Nanosci. 2011;7(4): 524-530.
28. Moddaresi M, Brown MB, Zhao Y, Tamburic S, Jones SA. The role of vehicle-nanoparticle interactions in topical drug delivery. Int J Pharm. 2010;400:176-182.
29. El-Hefian EA, Yahaya AH. Rheological study of chitosan and its blends: an overview. Maejo Int J Sci Technol. 2010;4(2):210-220.
30. Mucha M. Rheological characteristics of semi-dilute chitosan solutions. Macromol Chem Phys. 1997;198:471-484.
31. Hernández R, Zamora-Mora V, Sibaja-Ballestero M, Vega-Baudrit J, López D, Mijangos C. Influence of iron oxide nanoparticles on the rheological properties of hybrid chitosan ferrogels. J Colloid Interface Sci. 2009;339:53-59.
32. José Moura M, Margarida Figueiredo M, Helena Gil M. Rheological study of genipin cross-linked chitosan hydrogels. Biomacromolecules. 2007;8:3823-3829.
33. Jones DS, Woolfson AD, Brown AF. Textural, viscoelastic and mucoadhesive properties of pharmaceutical gels composed of cellulose polymers. Int J Pharm. 1997;151:223-233.
34. Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29-35.
35. Senyigit T, Tekmen I, Sonmez U, Santi P, Ozer O. Deoxycholate hydrogels of betamethasone-17-valerate intended for topical use: in vitro and in vivo evaluation. Int J Pharm. 2011;403:123-129.
36. Mugglestone CJ, Mariz S, Lane ME. The development and registration of topical pharmaceuticals. Int J Pharm. 2012;435:22-26.
37. Bach M, Lippold BC. Influence of penetration enhancers on the blanching intensity of betamethasone 17-benzoate. Int J Pharm. 1998;168: 97-108.
38. Herkenne C, Alberti I, Naik A, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res. 2008;25(1):87-103.
39. Haigh JM, Meyer E, Smith EW, Kanfer I. The human skin blanching assay for in vivo topical corticosteroid assessment II. Subject- and observer-dependent variation in blanching responses. Int J Pharm. 1997;152:185-192.
40. Pershing LK, Bakhtian S, Poncelet G, Corlett JL, Shah VP. Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci. 2002;91: 1312-1323.
41. Montenegro L, Ademola JI, Bonina FP, Maibach HI. Effect of application time of betamethasone-17-valerate 0.1% cream on skin blanching and stratum corneum drug concentration. Int J Pharm. 1996;140: 51-60.
42. Woodford R, Barry BW. Bioavailability and activity of betamethasone 17-benzoate in gel and cream formulations: comparison with proprietary topical corticosteroid preparations in the vasoconstrictor assay. Curr Ther Res. 1974;16(4):338-345.
43. Lamaud L, Lambrey B, Schalla W, Schaefer H. Correlation between transepidermal water loss and penetration of drugs. J Invest Dermatol. 1984;82:556-563.
44. Wester RC, Maibach HI. Human percutaneous absorption and transepidermal water loss (TEWL) correlation. In: Bronaugh RL, Maibach HI, editors. Percutaneous Absorption. Florida: Taylor and Francis, Boca Raton; 2005:509-520.